Sartorius has joined the European Molecular Biology Laboratory’s (EMBL) Corporate Partnership Program of initiatives, designed to offer industrial support to academic training and education. Sartorius will in addition fund travel bursaries for teachers attending courses run by EMBL’s Learning Laboratory for the Life Sciences, or ELLS.

The EMBL Corporate Partnership Program includes training courses, conference sponsorship, and workshops for young scientists at the EMBL International Center for Advanced Training (EICAT). “By focusing on professional training at all levels, and ensuring that the next generation of young talent has access to the latest knowledge, we aim to support the scientific community to reach its maximum potential,” commented Karen Storm, vp for marketing at Sartorius’s Lab Products & Services Division.

Yesterday, EMBL and GSK announced a 5-year collaboration to develop new technologies to help scientists understand and predict how drugs impact on the body at the molecular cellular and organ levels. The goal is to aid the discovery of new drug targets and drug compounds. GSK will fund a joint EMBL-GSK postdoctoral program and additional collaborative research activities. GSK and EMBL have existing scientific partnerships, and Cellzome, GSK’s drug discovery platform business, is sited at the EMBL Heidelberg campus. Cellzome was originally an EMBL spinout and was purchased by GSK in 2012.

Pharmaceutical and laboratory equipment provider Sartorius operates two divisions—Bioprocess Solutions and Lab Products & Services. The firm reported overall groups sales of €1.3 billion (approximately $1.38 billion) in 2016, an 18.2% increase on sales in 2015. EBIDTA was up 23.6%, at €325.4 million (approximately $347 million). Sales by the Bioprocess Solutions division, which offers single-use products for biopharmaceutical manufacturing, were up 22.1% (in constant currency) to €975 million (roughly $1.04 billion). The Lab Products & Services division, which offers instruments and consumables for the pharma and public research sectors, reported a 7.9% increase in sales, to €325.3 million (approximately $347 million).

Previous articleEye Study Advances Ability to Improve Clinical Measurement of Retinal Degeneration
Next articleAmygdala Acquires Phase II-Ready Addiction Candidate from Gilead